lubbock glp-1 medical weight loss Management in GLP-1 Weight Loss Injections in

Changing one without professional guidance can lead to either subtherapeutic levels (wasting medication and money) or supratherapeutic levels (unnecessary side effects and potential complications)

Not every patient is a candidate for every medication

Lipodystrophyabnormal accumulation or loss of subcutaneous fat at injection sitescan develop with repeated injections in the same location

The gut microbiota to the brain axis in the metabolic control

Wait until your next regularly scheduled day to take your next dose

In the STEP 1 semaglutide trial (Wilding et al., NEJM , 2021) and the SURMOUNT-1 tirzepatide trial (Jastreboff et al., NEJM , 2022), nausea affected roughly 44% of semaglutide patients and about 24% of tirzepatide patients at the maximum dose